生长抑素类似物联合肽受体放射性核素治疗晚期分化良好的神经内分泌肿瘤。

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.

机构信息

Fondazione IRCCS Istituto Nazionale Tumori Milano, ENETS Center of Excellence, Department of Medical Oncology, Milan, Italy.

Postgraduation School in Radiodiagnostics, Università degli Studi di Milano, Milan, Italy.

出版信息

Future Oncol. 2019 Sep;15(26):3015-3024. doi: 10.2217/fon-2019-0138. Epub 2019 Aug 19.

DOI:10.2217/fon-2019-0138

PMID:31424273

Abstract

Data from 69 well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy + somatostatin analogs (SSAs) after SSA treatment failure were evaluated. We identified two groups: S1 - patients who kept the same SSA treatment beyond progression; S2 - patients who switched the SSA with another SSA after progression. Median progression-free survival was 53 and 127 months in S1 and S2, respectively (p = 0.001; hazard ratio: 0.31; 95% CI: 0.15-0.63). Median overall survival was 69 versus 150 months in S1 and S2, respectively (p = 0.004; hazard ratio: 0.32; 95% CI: 0.14-0.71). In patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionucleotide therapy plus SSA after SSA failure, the 'switch' strategy of SSA after progression improve progression-free survival and overall survival.

摘要

对 69 例因 SSA 治疗失败后接受肽受体放射性核素治疗+生长抑素类似物（SSA）治疗的分化良好的胃肠胰神经内分泌肿瘤患者的数据进行了评估。我们确定了两组：S1-进展后继续使用相同 SSA 治疗的患者；S2-进展后改用另一种 SSA 的患者。S1 和 S2 组的中位无进展生存期分别为 53 和 127 个月（p=0.001；风险比：0.31；95%CI：0.15-0.63）。S1 和 S2 组的中位总生存期分别为 69 个月和 150 个月（p=0.004；风险比：0.32；95%CI：0.14-0.71）。在因 SSA 失败后接受肽受体放射性核素治疗+SSA 治疗的晚期分化良好的胃肠胰神经内分泌肿瘤患者中，进展后 SSA 的“切换”策略可改善无进展生存期和总生存期。